BRIEF

on BIOMERIEUX (EPA:BIM)

BioMérieux Introduces Equine Endocrinology Testing for Enhanced Horse Health

Stock price chart of BIOMERIEUX (EPA:BIM) showing fluctuations.

bioMérieux, a leader in in vitro diagnostics, has launched its new endocrinology tests for equines. These include VIDAS® Equine INSULIN and VIDAS® Equine ACTH. These tests offer laboratory-standard results directly at the Point of Care. VIDAS® Equine INSULIN provides results in around 20 minutes, aiding in diagnosing and managing Equine Metabolic Syndrome. VIDAS® Equine ACTH assesses adrenocorticotropic hormone levels in about 45 minutes, helping detect Equine Cushing’s Disease.

The tests are particularly crucial because 18%-27% of horses over 15 show symptoms of insulin dysregulation or Cushing’s Disease. This innovation will enhance diagnostic capability in the UK and France, with plans for international expansion. It follows bioMérieux's introduction of VETFIRETM, a PCR test, demonstrating the company's commitment to improving veterinary diagnostics.

R. H.

Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.

Click here to consult the press release on which this article is based

See all BIOMERIEUX news